Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $80.67 Consensus PT from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $81.60.

Several research firms have recently commented on HALO. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. UBS Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday. Finally, Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th.

Halozyme Therapeutics Stock Up 5.3%

HALO opened at $69.82 on Thursday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business has a 50 day simple moving average of $66.44 and a 200-day simple moving average of $68.71. The stock has a market capitalization of $8.28 billion, a P/E ratio of 25.12, a P/E/G ratio of 0.27 and a beta of 0.88. Halozyme Therapeutics has a 12 month low of $51.06 and a 12 month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same period last year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts anticipate that Halozyme Therapeutics will post 7.6 earnings per share for the current fiscal year.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, suggesting improving profit expectations for Halozyme Therapeutics. Halozyme Therapeutics article
• Positive Sentiment: Analysts now see stronger earnings in several quarters, including Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which may reinforce the stock’s valuation outlook. Halozyme Therapeutics article
• Neutral Sentiment: There was also a small increase in one near-term estimate for Q4 2026, while Q2 2026 was trimmed slightly and Q1 2028 was revised lower, indicating a mostly constructive but not uniformly higher forecast profile. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were executed under pre-arranged 10b5-1 plans, which usually makes them less concerning to investors than discretionary selling. Halozyme Therapeutics article

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the transaction, the director owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares of the company’s stock, valued at $974,014.80. The trade was a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 122,107 shares of company stock valued at $8,254,834. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of HALO. Empowered Funds LLC purchased a new position in Halozyme Therapeutics during the first quarter worth $755,000. Acadian Asset Management LLC purchased a new position in Halozyme Therapeutics during the first quarter worth $195,000. Hsbc Holdings PLC increased its position in Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. grew its position in shares of Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.